Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Brian Tomlinson, Paul Chan, Yuzhen Zhang & Christopher Wai Kei Lam. (2020) Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy 21:17, pages 2137-2151.
Read now
Read now
Chao Liu, Hong Lu, Fei Yuan, Wei-Li Chen, Hong-Rong Xu, Hui Li, Cheng-Pang Hsu, Ogo Egbuna, Jihua Wu, Clapton Dias, Bassam Abosaleem, Jitesh Rana, Maria Laura Monsalvo, Xue-Ning Li & Zhigang Yu. (2019) A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects. Clinical Pharmacology: Advances and Applications 11, pages 145-153.
Read now
Read now
Slobodan M. Janković, Danka Tešić, Jelena Anđelković & Marina Kostić. (2018) Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 461-474.
Read now
Read now
Najmeh Ahangari, Majid Ghayour Mobarhan, Amirhossein Sahebkar & Alireza Pasdar. (2018) Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. Annals of Medicine 50:4, pages 303-311.
Read now
Read now
Michel Farnier. (2017) Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Expert Review of Cardiovascular Therapy 15:12, pages 923-932.
Read now
Read now
Cezary Wójcik. (2017) Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate Medicine 129:8, pages 801-810.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy 17:11, pages 1447-1461.
Read now
Read now
Amita Singh & Michael Davidson. (2016) Update on PCSK9 therapies for the treatment of dyslipidemia. Expert Review of Endocrinology & Metabolism 11:1, pages 87-95.
Read now
Read now
Articles from other publishers (35)
Yongjun Li, Mingming Yang, Xi Chen, Rui Zhang, Jing Li, Xiaoguo Zhang, Pengfei Zuo & Genshan Ma. (2022) Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. Journal of Interventional Cardiology 2022, pages 1-5.
Crossref
Crossref
Mingqi Ouyang, Chenyu Li, Die Hu, Daoquan Peng & Bilian Yu. (2022) Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. Clinica Chimica Acta.
Crossref
Crossref
Nicola Ferri, Massimiliano Ruscica, Maria Giovanna Lupo, Marco Vicenzi, Cesare R. Sirtori & Alberto Corsini. (2022) Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacological Research 184, pages 106439.
Crossref
Crossref
Liu Yang, Yan-Yan Xiao, Liang Shao, Chang-Sheng Ouyang, Yao Hu, Bin Li, Li-Feng Lei & Hong Wang. (2022) Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report. World Journal of Clinical Cases 10:19, pages 6728-6735.
Crossref
Crossref
Aida Collado, Elena Domingo, Laura Piqueras & Maria-Jesus Sanz. (2021) Primary hypercholesterolemia and development of cardiovascular disorders: Cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction. The International Journal of Biochemistry & Cell Biology 139, pages 106066.
Crossref
Crossref
Victoria A. Korneva, Tatjana Yurjevna Kuznetsova & Ulrich Julius. (2021) Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. Biomedicines 9:9, pages 1271.
Crossref
Crossref
M. Farnier. (2021) Nuevos hipolipidemiantes. EMC - Tratado de Medicina.
Crossref
Crossref
Pragyi Shrestha, Saritha Adepu, Romain R. Vivès, Rana El Masri, Astrid Klooster, Fleur Kaptein, Wendy Dam, Stephan J. L. Bakker, Harry van Goor, Bart van de Sluis & Jacob van den Born. (2021) Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction. Journal of the American Society of Nephrology 32:6, pages 1371-1388.
Crossref
Crossref
Lili Wang, Camilo Breton, Claude C. Warzecha, Peter Bell, Hanying Yan, Zhenning He, John White, Yanqing Zhu, Mingyao Li, Elizabeth L. Buza, Derek Jantz & James M. Wilson. (2021) Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Molecular Therapy 29:6, pages 2019-2029.
Crossref
Crossref
Piotr Pęczek, Mateusz Leśniewski, Tomasz Mazurek, Lukasz Szarpak, Krzysztof J. Filipiak & Aleksandra Gąsecka. (2021) Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life 11:6, pages 466.
Crossref
Crossref
Paola Sabrina Buonuomo, Gerarda Mastrogiorgio, Giovanna Leone, Ippolita Rana, Michaela Veronika Gonfiantini, Marina Macchiaiolo, Davide Vecchio, Maria Gnazzo & Andrea Bartuli. (2021) Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia. Atherosclerosis 324, pages 148-150.
Crossref
Crossref
Donald J. AbrahamScott D. Edmondson, Duane A. Burnett & Harry R. DavisJrJr. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
36
.
Aida Collado, Elena Domingo, Patrice Marques, Eva Perello, Sergio Martínez-Hervás, Laura Piqueras, Juan F. Ascaso, José T. Real & Maria-Jesus Sanz. (2021) Oral Unsaturated Fat Load Impairs Postprandial Systemic Inflammation in Primary Hypercholesterolemia Patients. Frontiers in Pharmacology 12.
Crossref
Crossref
Bruce A. Warden, Sergio Fazio & Michael D. Shapiro. (2020) The PCSK9 revolution: Current status, controversies, and future directions. Trends in Cardiovascular Medicine 30:3, pages 179-185.
Crossref
Crossref
Bruce A. Warden, Joshua R. Miles, Carlota Oleaga, Om P. Ganda, P. Barton Duell, Jonathan Q. Purnell, Michael D. Shapiro & Sergio Fazio. (2020) Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. American Journal of Preventive Cardiology 1, pages 100012.
Crossref
Crossref
Raul D. Santos, Evan A. Stein, G. Kees Hovingh, Dirk J. Blom, Handrean Soran, Gerald F. Watts, J. Antonio G. López, Sarah Bray, Christopher E. Kurtz, Andrew W. Hamer & Frederick J. Raal. (2020) Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology 75:6, pages 565-574.
Crossref
Crossref
Heidi T. May, Joseph B. Muhlestein, Yuhui Ma, J. Antonio G. López, Blai Coll & John Nelson. (2019) Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiology and Therapy 8:1, pages 91-102.
Crossref
Crossref
Pierre Sabouret, Michel Farnier & Etienne Puymirat. (2019) Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?. La Presse Médicale 48:3, pages 227-237.
Crossref
Crossref
Aida Collado, Patrice Marques, Elena Domingo, Eva Perello, Herminia González-Navarro, Sergio Martinez-Hervás, José Real, Laura Piqueras, Juan Ascaso & Maria-Jesus Sanz. (2018) Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation. Journal of Clinical Medicine 8:1, pages 18.
Crossref
Crossref
Anum Saeed, Salim S. Virani, Peter H. Jones, Christie M. Ballantyne & Vijay Nambi. (2018) Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. Journal of Clinical Lipidology 12:5, pages 1141-1145.
Crossref
Crossref
Angela Pirillo & Alberico Luigi Catapano. (2018) Proprotein Convertase Subtilisin Kexin 9 Inhibitors. Cardiology Clinics 36:2, pages 241-256.
Crossref
Crossref
BinBin Zheng-Lin & Alberto Ortiz. (2018) Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 78:2, pages 215-229.
Crossref
Crossref
Donatella Zodda, Rosario Giammona & Silvia Schifilliti. (2018) Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy 6:1, pages 10.
Crossref
Crossref
Ellen Q. Wang, Anna Plotka, Joanne Salageanu, Catherine Sattler & Carla Yunis. (2017) Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]. Cardiovascular Therapeutics 35:5, pages e12278.
Crossref
Crossref
Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abrignani, Marcello Arca, Pasquale Perrone Filardi, Francesco Perticone, Alberico Catapano, Raffaele Griffo, Federico Nardi, Carmine Riccio, Andrea Di Lenarda, Marino Scherillo, Nicoletta Musacchio, Antonio Vittorio Panno, Giovanni Battista Zito, Mauro Campanini, Leonardo Bolognese, Pompilio Massimo Faggiano, Giuseppe Musumeci, Enrico Pusineri, Marcello Ciaccio, Enzo Bonora, Giorgio Cantelli Forti, Maria Pia Ruggieri, Claudio Cricelli, Francesco Romeo, Roberto Ferrari & Attilio Maseri. (2017) ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy. European Heart Journal Supplements 19:suppl_D, pages D3-D54.
Crossref
Crossref
Delia Susan-Resiga, Emmanuelle Girard, Robert Scott Kiss, Rachid Essalmani, Josée Hamelin, Marie-Claude Asselin, Zuhier Awan, Chutikarn Butkinaree, Alexandre Fleury, Armand Soldera, Yves L. Dory, Alexis Baass & Nabil G. Seidah. (2017) The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation. Journal of Biological Chemistry 292:5, pages 1573-1590.
Crossref
Crossref
M Levisetti, T Joh, H Wan, H Liang, P Forgues, B Gumbiner & PD Garzone. (2017) A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy. Clinical and Translational Science 10:1, pages 3-11.
Crossref
Crossref
A. Pirillo, G.D. Norata & A.L. Catapano. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
663
693
.
Ioanna Gouni‐Berthold, Olivier S. Descamps, Uwe Fraass, Elizabeth Hartfield, Kim Allcott, Ricardo Dent & Winfried März. (2016) Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. British Journal of Clinical Pharmacology 82:6, pages 1412-1443.
Crossref
Crossref
Michel Farnier. (2016) Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience. Current Opinion in Lipidology 27:6, pages 597-604.
Crossref
Crossref
Peter P. Toth. (2016) Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. The American Journal of Cardiology 118:6, pages 19A-32A.
Crossref
Crossref
Laura A. Della Badia, Nabil A. Elshourbagy & Shaker A. Mousa. (2016) Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Pharmacology & Therapeutics 164, pages 183-194.
Crossref
Crossref
Michel Farnier. (2016) Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports 18:7.
Crossref
Crossref
Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J Feinstein, Arman Qamar, Parag H Joshi, Kristopher J Swiger, Kathleen Byrne, Renato Quispe, Steven R Jones, Roger S Blumenthal & Seth S Martin. (2016) PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology 12:2, pages 139-148.
Crossref
Crossref
M. Orho-Melander. (2015) Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine 278:5, pages 433-446.
Crossref
Crossref